Novavax, Inc. (NASDAQ:NVAX) major shareholder Pharmaceuticals Ltd Cadila sold 3,000,000 shares of Novavax stock on the open market in a transaction dated Friday, March 21st. Novavax, Inc. (NASDAQ:NVAX) shares after opening at $4.94 moved to $5.00 on last trade day and at the end of the day closed at $4.68. Company price to sales ratio in past twelve months was calculated as 47.23 and price to cash ratio as 5.39. Novavax, Inc. (NASDAQ:NVAX) showed a negative weekly performance of -12.85%.
Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target raised by analysts at UBS AG from $185.00 to $202.00. They now have a “buy” rating on the stock. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares fell -7.99% in last trading session and ended the day on $159.79. ALXN return on equity ratio is recorded as 11.20% and its return on assets is 8.50%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) yearly performance is 73.05%.
Incyte Corporation (NASDAQ:INCY) had its price target upped by Argus from $65.00 to $85.00 in a research note issued to investors on Monday, American Banking & Market News reports. The firm currently has a buy rating on the stock. Incyte Corporation (NASDAQ:INCY) shares moved down -6.88% in last trading session and was closed at $59.41 while trading in range of $58.41 – $63.84 – Incyte Corporation (NASDAQ:INCY) year to date (YTD) performance is 17.34%.
Shares of Dyax (NASDAQ:DYAX) , a biopharmaceutical company focused on developing therapies surrounding plasma kallirrein-mediated (PKM) angioedemas, dipped as much as 12% after the company announced a common stock offering after the closing bell last night. Dyax Corp. (NASDAQ:DYAX) weekly performance is -3.79%. On last trading day company shares ended up $8.88. Dyax Corp. (NASDAQ:DYAX) distance from 50-day simple moving average (SMA50) is -4.13%. Analysts mean target price for the company is $13.08.